The structure previously assigned to the phenolic noraporphine alkaloid, (-)-norannuradhapurine has been confirmed by a total synthesis of the racemic alkaloid in which the key step involved the formation of the C ring by a radical-initiated cyclization. although inactive against Staphylococcus aureus ATCC25932, Escherichia coli ATCC10536 and Candida albicans ATCC90028, (±)-norannuradhapurine inhibits the production of NO, PGE 2 , TNF-α, IL-1β and IL-6 and the expression of iNOS and COX-2 in RAW 264.7 macrophages stimulated with LPS in vitro.
Introduction
(-)-Norannuradhapurine (1a) is a phenolic noraporphine alkaloid isolated for the first time from the bark and leaves of Polyalthia acuminate Thw. (Annonaceae) [1] and subsequently from the bark and wood of Fissistigma glaucescens (Hance) Merr. and the wood of Fissistigma oldhamii (Hemsl.) Merr. (Annonaceae) [2] . (-)-Norannuradhapurine has been shown to exhibit strong inhibition of adenosine 5'-diphosphate (ADP)-induced, collagen-induced and platelet-activating factor (1-O-alkyl-2-acetylsn-glycero-3-phosphocholine)-induced platelet aggregations [3] . In addition, (-)-norannuradhapurine has exhibited a broad spectrum of growth inhibitory activities against murine and human leukemic cells with IC 50 values around 3mM and it also has strong inhibitory effects on DNA, RNA and protein biosynthesis [4] . In view of these interesting biological activities and the fact that the alkaloid occurs only in minute quantities in Nature, we decided to undertake a total synthesis of the alkaloid to establish its structure and also to make it more accessible for anti-microbial and anti-inflammatory activity studies.
Results and Discussion

Synthesis
The strategy employed for the synthesis of (±)-norannuradhapurine (1a) was based on the construction of ring C by a radical-initiated cyclization which has proved successful in the syntheses of other aporphine alkaloids [5] [6] [7] [8] (Scheme 1).
For this purpose, the required starting materials were 3,4-methylene-dioxyphenethylamine (2) [9] and 2-benzyloxy-6-bromo-3-methoxyphenylacetic acid (3e). Thus, benzylation of 6-bromo-2-hydroxy-3-methoxybenzaldehyde [10] gave 3a, which was converted into 3b-e, respectively by conventional methods. Condensation of 2-benzyloxy-6-bromo-3-methoxy-phenylacetyl chloride (3f) with 3,4-methylenedioxyphenethylamine (2) gave amide 4, which was converted into 5 by a BischlerNapieralski reaction. Reduction of 5 with sodium borohydride gave 6a which was treated with trifluoroacetic anhydride to give 6b. Treatment of 6b with tributyltin hydride and 2,2′-azobis(isobutyronitrile) afforded 1b in 40% yield. The structure of 1b was supported by 1 H-NMR data, in which H-11 gave rise to an unusually low-field doublet at δ 7.86 and the 1,2-methylenedioxy protons gave rise to an AB quartet at δ 6.02 (J = 1.20 Hz ), characteristic of an aporphine moiety bearing a methylenedioxy group at those positions. Attempts to remove the trifluoroacetyl group from 1b under basic conditions were fruitless, possibly due to steric hindrance of the benzyloxy group on ring D. Fortunately, catalytic hydrogenolysis of 1b went smoothly to give 1c, whose trifluoroacetyl group was smoothly removed to give (±)-norannuradhapurine (1a), the 1 H-NMR spectral data of which were in excellent agreement with those reported for natural (-)-norannuradhapurine [1] . Since the 13 C-NMR spectral data of the natural alkaloid have not been previously reported, we have reported here these data from spectra measured both in CDCl 3 and d 6 -DMSO for future reference. 
Biological activity
At a concentration of 256 μg/mL, (±)-norannuradhapurine was inactive Staphylococcus aureus ATCC25932 Escherichia coli ATCC10536 and Candida albicans ATCC90028. In the course of our studies on its anti-inflammatory activity, we have found that (±)-norannuradhapurine inhibits NO production in murine macrophage RAW 264.7 cells stimulated with LPS ( Figure 1 ). Next we investigated the effect of (±)-norannuradhapurine on the release of PGE 2 . Compared with the untreated control, LPS (1 μg/mL) induced a great production of PGE 2 in RAW 264.7 cells. (±)-Norannuradhapurine (1-5 mg/mL) inhibited the production of PEG 2 in RAW 264.7 cells stimulated with LPS in a concentration-dependent manner (Figure 2 ). To elucidate the mechanism of the inhibitory effect of (±)-norannuradhapurine on NO and PGE 2 production, we investigated their effects on iNOS and COX-2 expression levels, respectively. In response to LPS, the iNOS and COX-2 induction were markedly increased, (±)-norannuradhapurine significantly decreased the iNOS and COX-2 protein expression in a concentration-dependent manner ( Figures 3, 4) . In contrast to iNOS and COX-2, (±)-norannuradhapurine had no effect on the expression of β-actin and COX-1 (data not shown). This finding indicates that (±)-norannuradhapurine could suppress NO and PGE 2 production in LPS-stimulated RAW 264.7 cells by inhibiting iNOS and COX-2 protein expression, respectively. It has been reported that cytokines such as TNF-α, IL-1β and IL-6 are proinflammatory in vitro as well as in vivo [14] . The present study also demonstrated that (±)-norannuradhapurine has inhibitory effects on the production of TNF-α, IL-1β and IL-6 in LPSstimulated RAW 264.7 cells. As shown in Figures 5, 6 , 7, LPS-induced productions of TNF-α, IL-1β and IL-6 were significantly inhibited by (±)-norannuradhapurine in a concentration-dependent manner. In addition, the cytotoxic effect of (±)-norannuradhapurine was evaluated in the absence or presence of LPS, (more than 95% cell viability). There is no significant difference on cell viability when treated with (±)-norannuradhapurine at all concentrations used (1-5 μg/mL) in the absence or presence of LPS. 
Conclusions
In conclusion, we found that (±)-norannuradhapurine has anti-inflammatory activity, it inhibits the production of NO, PGE 2 , TNF-α, IL-1β and IL-6 and the expression of iNOS and COX-2 in macrophages stimulated with LPS in vitro. From these results it is expected that (±)-norannuradhapurine could be potentially useful for the treatment inflammatory diseases. 
Experimental
General
Melting points were determined on a Stuart SMP2 apparatus and are uncorrected. Ultraviolet spectra were recorded on methanol solutions with a Jasco V-530 UV-VIS spectrophotometer. Infrared spectra were recorded on Nujol mulls unless stated otherwise with a Perkin-Elmer Spectrum GX FT-IR spectrophotometer.
1 H-and 13 C-NMR magnetic resonance spectra were recorded on CDCl 3 solutions, unless stated otherwise, at 300 MHz for 1 H and 75 MHz for 13 C with a Bruker AVANCE 300 spectrometer. Tetramethylsilane was used as the internal standard. Mass spectra were measured on a Hewlett Packard 5989B spectrometer. Elemental microanalyses were performed with a Perkin-Elmer 2400 elemental analyser. 
2-Benzyloxy-6-bromo-3-methoxybenzaldehyde (3a
2-Benzyloxy-6-bromo-3-methoxybenzyl alcohol (3b
2-Benzyloxy-6-bromo-3-methoxybenzyl chloride (3c
2-Benzyloxy-6-bromo-3-methoxybenzyl cyanide (3d
2-Benzyloxy-6-bromo-3-methoxyphenylacetic acid (3e
2-(2-Benzyloxy-6-bromo-3-methoxyphenyl)-N-(3,4-methylenedioxyphenethyl)acetamide (4)
. A mixture of 2-benzyloxy-6-bromo-3-methoxyphenylacetic acid (3e, 21.5 g) and thionyl chloride (20.3 g) in benzene (150 mL) was refluxed for 1 h, then the solvent and excess thionyl chloride were removed in vacuo. The resulting crude 2-benzyloxy-6-bromo-3-methoxyphenylacetyl chloride (3f) was dissolved in chloroform (200 mL) and added portionwise to a mixture of 2-(3,4-methylenedioxyphenyl)ethylamine (2, 11.2 g) [9] in chloroform (100 mL), sodium hydrogen carbonate (25 g) and ice (200 g). The mixture was stirred at room temperature for 3 h. The chloroform layer was washed with 10% sodium carbonate (3 x100 mL), water (2 x100 mL), 5% HCl (3 x 100 mL), brine and then dried. Removal of the solvent under vacuum gave a pale yellow solid which was recrystallized from ethanol to give amide 4 as a pale yellow solid (21.6 g , 70.8%), m.p. 143-144°C; UV λ max nm (MeOH) (log ε ) 231sh (4. (5) . A solution of amide 4 (6.03 g) and phosphorus oxychloride (19.4 g) in benzene (50 mL) was refluxed for 2 h. The excess reagent and solvent were removed under vacuum. The resulting brown residue was shaken with chloroform (80 mL) and dilute ammonium hydroxide (60 mL). The chloroform layer was washed with water (3 x 60 mL) and then dried. Removal of the solvent under vacuum followed by recrystallisation from ethanol gave dihydroisoquinoline 5 as pale yellow prisms (5.64 g, 97.1%), m.p. 81-82°C; UV λ max nm (log ε) 227sh (4. 
1-(2-Benzyloxy-6-bromo-3-methoxybenzyl)-6,7-methylenedioxy-3, 4-dihydroisoquinoline
1-(2-Benzyloxy-6-bromo-3-methoxybenzyl)-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline (6a).
Sodium borohydride (2.0 g) was added portionwise to a stirred solution of dihydroisoquinoline 5 (18.2 g) in ethanol (310 mL) and the mixture was refluxed for 1 h. Chloroform (200 mL) was added and the mixture was washed with water (4 x 200 mL), brine and then dried. Removal of the solvent under vacuum gave tetrahydroisoquinoline 6a as a yellow-red viscous oil (14.8 g, 81.0%) which failed to crystallise and was used in the next step without further purification. 1 
2-Trifluoroacetyl-1-(2-benzyloxy-6-bromo-3-methoxybenzyl)-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline (6b)
. Trifluoroacetic anhydride (38.5 g) was added dropwise to a stirred mixture of tetrahydroisoquinoline 6a (14.8 g) and triethylamine (26.6 g) in chloroform (230 mL) at 0-10°C. Stirring was continued at room temperature for 3 h. Chloroform (150 mL) was added and the chloroform layer was washed with 10% sodium hydrogen carbonate (4 x 200 mL), 10% HCl (3 x 250 mL), brine and then dried. Removal of the solvent gave a red-brown viscous oil which crystallized from ethanol to give trifluoroacetamide 6b as a pale yellow solid (7. 8-Benzyloxy-9-methoxy-1,2-methylenedioxy-6-trifluoroacetylnoraporphine (1b). A solution of 2,2′-azobis(isobutyronitrile) (1.59 g) and tributyltin hydride (6.18 g) in toluene (70 mL) was added in 6 equal portions over 2.5 h to a refluxing solution of trifluoroacetamide 6b (6.23 g) in toluene (110 mL). The resulting mixture was then refluxed for 24 h. The solvent was removed under vacuum and the resulting yellow residue was dissolved in acetonitrile (500 mL) and washed with hexane (5 x 200 mL) and then dried. Removal of the solvent under vacuum gave a yellow solid which was triturated from ethanol to give noraporphine 1b as colourless needles (2. Cytotoxicity assay. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay was performed according to the method previously described [13] . MTT solution was added at a concentration of 50 μg/mL into each well, which also contain 1, 2.5 and 5 μg/mL of (+)-3-methoxynordomesticine. After 4 h of incubation at 37 ºC, the medium was discarded and the formazan blue, which formed in the cells, was dissolved in 50 μl DMSO. The optical density at 540 nm was determined with a microplate reader. The optical density of formazan formed in control (untreated) cells was taken as 100% of viability.
